{"entity":{"id":"garnet","kind":"trial","name":"GARNET","aka":[],"tldr":"GARNET showed that the PD-1 antibody dostarlimab produced lasting responses in about four in ten women with mismatch repair-deficient endometrial cancer that had returned after chemotherapy, which won the drug its first approvals.","summary":"GARNET was a large phase 1 dose-finding and expansion study of dostarlimab, a PD-1 antibody, in advanced solid tumours. Its expansion cohorts enrolled recurrent or advanced endometrial cancer after platinum, split by mismatch repair status, and a cohort of non-endometrial mismatch repair-deficient tumours. The primary endpoints for the expansion cohorts were objective response rate and duration of response by independent review.\n\nIn the mismatch repair-deficient endometrial cohort roughly four in ten patients responded and most responses were durable, with a lower response rate in the proficient cohort. Dostarlimab received accelerated approval in the United States in April 2021 for mismatch repair-deficient recurrent endometrial cancer and later a tumour-agnostic approval for mismatch repair-deficient solid tumours; the RUBY trial then moved it into first line with chemotherapy.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT02715284","url":"https://clinicaltrials.gov/study/NCT02715284"}],"tags":["subtype-trials"],"related":[],"cancers":["endometrial-mmr-deficient","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ana-oaknin"],"bottlenecks":[],"keyPapers":["paper-garnet-dostarlimab-oaknin-jama-oncol-2020"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02715284","phase":"1","setting":"Advanced solid tumours, with expansion cohorts in mismatch repair-deficient and mismatch repair-proficient recurrent or advanced endometrial cancer after platinum chemotherapy and in other mismatch repair-deficient tumours: single-arm dostarlimab","sponsor":"Tesaro (GSK)","result":"Dostarlimab produced durable objective responses in roughly four in ten patients with mismatch repair-deficient recurrent endometrial cancer; accelerated approval in April 2021.","yearReported":2020,"enrolled":729,"outcomes":[]},"route":"/trials/garnet/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}],"person":[{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/"}],"paper":[{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/"}]}}